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Combined Heart Failure Device
Diagnostics Identify Patients at Higher
Risk of Subsequent Heart Failure Hospitalizations
Results From PARTNERS HF (Program to
Access and Review Trending Information and Evaluate
Correlation to Symptoms in Patients With Heart Failure) Study
David J. Whellan, MD, MHS,* Kevin T. Ousdigian, MSEE, MSIE,† Sana M. Al-Khatib, MD, MHS,‡
Wenji Pu, PHD,† Shantanu Sarkar, PHD,† Charles B. Porter, MD,§ Behzad B. Pavri, MD,*
Christopher M. O’Connor, MD,‡ for the PARTNERS Study Investigators
Philadelphia, Pennsylvania; Minneapolis, Minnesota; Durham, North Carolina; and Kansas City, Kansas
Objectives We sought to determine the utility of combined heart failure (HF) device diagnostic information to predict clini-
cal deterioration of HF in patients with systolic left ventricular dysfunction.
Background Some implantable devices continuously monitor HF device diagnostic information, but data are limited on the
ability of combined HF device diagnostics to predict HF events.
Methods The PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms
in Patients With Heart Failure) was a prospective, multicenter observational study in patients receiving cardiac
resynchronization therapy (CRT) implantable cardioverter-defibrillators. HF events were independently adjudi-
cated. A combined HF device diagnostic algorithm was developed on an independent dataset. The algorithm was
considered positive if a patient had 2 of the following abnormal criteria during a 1-month period: long atrial fi-
brillation duration, rapid ventricular rate during atrial fibrillation, high (60) fluid index, low patient activity, ab-
normal autonomics (high night heart rate or low heart rate variability), or notable device therapy (low CRT pacing
or implantable cardioverter-defibrillator shocks), or if they only had a very high (100) fluid index. We used uni-
variate and multivariable analyses to determine predictors of subsequent HF events within a month.
Results We analyzed data from 694 CRT defibrillator patients who were followed for 11.7  2 months. Ninety patients
had 141 adjudicated HF hospitalizations with pulmonary congestion at least 60 days after implantation. Pa-
tients with a positive combined HF device diagnostics had a 5.5-fold increased risk of HF hospitalization with
pulmonary signs or symptoms within the next month (hazard ratio: 5.5, 95% confidence interval: 3.4 to 8.8,
p  0.0001), and the risk remained high after adjusting for clinical variables (hazard ratio: 4.8, 95% confidence
interval: 2.9 to 8.1, p  0.0001).
Conclusions Monthly review of HF device diagnostic data identifies patients at a higher risk of HF hospitalizations within the
subsequent month. (PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correla-
tion to Symptoms in Patients With Heart Failure; NCT00279955). (J Am Coll Cardiol 2010;55:1803–10)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.089B
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Combined HF Device Diagnostics Predict HF April 27, 2010:1803–102008, HF inpatient costs were
approximately $18.8 billion (1,2).
The ability to predict which pa-
tients will subsequently be hospi-
talized for HF is limited. Tradi-
tional evaluative measures such
as physical signs and symptoms
are poorly associated with hemo-
dynamics and are typically only
assessed intermittently; conse-
quently, they may not identify pa-
tients in time for intervention to
prevent imminent adverse events.
Implantable cardioverter-defi-
brillators (ICDs) and cardiac re-
synchronization therapy and defi-
brillator (CRT-D) are recom-
mended by practice guidelines as a
lass I therapy for a large number of HF patients based on
linical trial evidence showing a significant reduction in
ospitalization and mortality with their use (3,4). Expert
onsensus has recognized the utility of reviewing the HF
evice diagnostic information from these devices, and the
PT (Current Procedure Terminology) codes now include
eview of the HF device diagnostics in person or remotely at
onthly intervals (5).
Previous studies have demonstrated the ability of indi-
idual pieces of HF device diagnostic data, such as hemo-
ynamics (pressure or fluid index derived from intrathoracic
mpedance) or autonomics to predict HF events and/or
hange outcomes (6–9). Some investigators have observed
lose associations between changes in individual HF device
iagnostics and HF events (7). Preliminary review suggests
hat combining HF device diagnostic data into a single
lgorithm may improve the overall ability to risk-stratify HF
atients. However, the clinical utility of an algorithm that
ombines multiple HF device diagnostic parameters has not
een investigated.
The PARTNERS HF (Program to Access and Review
rending Information and Evaluate Correlation to Symp-
oms in Patients With Heart Failure) was a prospective,
onrandomized, multicenter observational study designed
o determine the potential utility of combined HF device
iagnostic information to predict the clinical deterioration
f ambulatory HF patients when reviewed at routine
ollow-up intervals. The primary hypothesis of the study
as that combining HF device diagnostic data would
nhance the ability to risk-stratify patients for subsequent
F events.
ethods
tudy patients. The design of the PARTNERS HF Study
as described in a previous publication (10). The key
Abbreviations
and Acronyms
CI  confidence interval
HF  heart failure
ICD  implantable
cardioverter-defibrillator
CRT  cardiac
resynchronization therapy
CRT-D  cardiac
resynchronization therapy
and defibrillator
HCU  health care
utilization
HR  hazard ratio
NYHA  New York Heart
Associationatient inclusion criteria were a left ventricular ejection araction 35%, New York Heart Association (NYHA)
unctional class III or IV, intrinsic QRS duration 130 ms,
nd use of a commercially available CRT-D system
Medtronic Models 7297, 7303, 7277, 7289, or C154DWK;
edtronic Inc., Minneapolis, Minnesota). The key exclu-
ion criteria were acute coronary intervention within the
ast month, permanent atrial arrhythmias, a history of heart
ransplantation, and end-stage renal disease requiring
ialysis.
This observational trial was undertaken at 100 sites
hroughout the U.S. Enrollment began in June 2004 and
nded in February 2007, with follow-up completed in April
008. The study was approved by the institutional review
oard at each participating institution. All patients provided
nformed consent.
tudy design and event definitions. Patients were fol-
owed for 12 months after enrollment (defined as implan-
ation date or consent date, whichever occurred later).
tandard clinical evaluations occurred at 3, 6, 9, and 12
onths after enrollment. At each follow-up visit, the
ollowing information was collected: NYHA functional
lassification, American College of Cardiology/American
eart Association stage A through D classification, and
atient cardiovascular medications. Additionally, each pa-
ient’s CRT-D memory was interrogated to retrieve the HF
evice diagnostic data, which were then stored in a database
or subsequent analysis.
Throughout the study, data on all cardiovascular-related
dverse events and deaths were collected. All adverse events
nd deaths were independently adjudicated by the Adverse
vent Advisory Committee. This committee classified each
dverse event as cardiovascular or not cardiovascular and
djudicated the event as HF related only if it resulted in
orsening HF. The Adverse Event Advisory Committee
urther determined whether the HF events were associated
ith signs and/or symptoms of pulmonary congestion. The
rimary end point was the number of HF hospitalizations
ith pulmonary congestion, and the secondary end point
as the number of HF health care utilization (HCU)
vents, defined as unscheduled office visits, urgent care
isits, emergency department visits, or hospitalization, with
ulmonary congestion. The committee members were
linded to the patients’ HF device diagnostic parameters.
ombined HF device diagnostic algorithm development.
n addition to providing CRT and ICD therapy, the devices
sed in this study had the capability to continuously monitor,
ecord, and display various HF device diagnostic parameters
eferred to as the Cardiac Compass diagnostic report (10). The
ndividual algorithms described in Table 1 were specified
efore the PARTNERS HF analysis and have been used to
ag significant observations from the trends in Medtronic
CDs and CRT-Ds that were introduced in 2003 and 2004 or
ased on previous analyses. A low activity threshold (1 h of
ctivity per day) was fixed for all patients and was based on a
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April 27, 2010:1803–10 Combined HF Device Diagnostics Predict HFrevious analysis that led to this threshold being used in
edtronic released ICDs/CRT-D.
To determine the appropriate combined HF device di-
gnostic threshold criteria for identifying prospective risk of
orsening HF, an independent internal development data-
et (n  819 patients) from a separate clinical registry trial
NCT00277524) was evaluated to determine the optimal
umber of these individual criteria that needs to be met to
rigger the combined HF device diagnostic algorithm. We
argeted having the algorithm trigger in less than a quartile
f evaluations to maintain specificity. We determined that
equiring only 1 criterion to be met would trigger the
lgorithm too often (43% evaluations), requiring 3 criteria
ould trigger too infrequently (3% evaluations), whereas
equiring 2 criteria (14%) most closely matched our prede-
ermined goal. Based on that analysis and previously pub-
ished data on the specificity of the intrathoracic impedance
uid index, the final prospectively identified criteria in-
luded a fluid index 100  days (9) or any 2 of the
ollowing criteria met during 1 evaluation period: long atrial
brillation (AF) duration, rapid ventricular rate during AF,
high (60) fluid index, low patient activity, high night
eart rate, low heart rate variability, low CRT pacing, or
CD shocks.
HF device diagnostic data from the first 60 days after
mplantation or enrollment were censored to establish the
eference impedance. Patients with5 months of follow-up
r without the intrathoracic impedance HF device diagnos-
ardiac Compass HF Device Diagnostic Parameters and AlgorithmsTable 1 Cardiac Compass HF Device Diagnostic Parameters an
HF Device Diagnostic
Parameter Description
AF duration The AF duration trend records the total time spent in
detection algorithm for AF has been proven to be
Ventricular rate during AF This trend computes the daily average ventricular rat
that day (12).
Fluid index (OptiVol) The fluid index corresponds to changes in thoracic flu
is the cumulative difference between the daily ave
reference intrathoracic impedances. The intrathora
from the voltage measured from an asynchronous
right ventricular lead and the device case (8,9).
Patient activity This trend measures the total time active per day using
A minute is considered active if the counts exceed a
approximately 70 steps/min (7).
Night heart rate This trend measures the average ventricular rate from
HRV The median atrial heart rate is determined every 5 m
computed each day. HRV is not computed if 80%
or AT/AF (7).
% of pacing CRT This trend records the percentage of ventricular pacin
ICD shock for potentially
lethal VT/VF
This trend records whether a patient has received an
episode detected as VT/VF and includes both appr
shocks (14).
F  atrial fibrillation; AT/AF  atrial tachycardia/atrial fibrillation; CRT  cardiac resynchronizat
T/VF  ventricular tachycardia/ventricular fibrillation.ics were excluded from the analysis.tatistical analysis. To evaluate the temporal dependency
f the detection criteria, retrospective evaluations for the
rimary analysis were simulated every 15 days (semi-
onthly), every 30 days (monthly), and also every 90 days
quarterly). Each simulation included: 1) a retrospective HF
evice diagnostic evaluation period to assess the patient’s
F risk based on the HF device diagnostic trends; and 2) a
rospective risk evaluation period to observe the first HF
vent occurrence (Fig. 1). Both the retrospective evaluation
orithms
Algorithm
a daily basis; the
accurate (11).
AF 6 h on at least 1 day in patients without
persistent AF (7 consecutive days with 23 h AF)
rring during AF on AF  24 h and the average ventricular rate during AF
90 beats/min on at least 1 day
ls. The fluid index trend
nd patient-specific
pedance is calculated
t applied between the
High fluid index on at least 1 day; thresholds included
60, 80, and 100
citive accelerometer.
old equal to walking
Average patient activity 1 h over 1 week
(nonoverlapping weekly windows)
M (midnight) to 4 AM (7). Average night heart rate 85 beats/min for
7 consecutive days (nonoverlapping weekly
windows)
a variability value is
e time is atrial pacing
HRV 60 ms everyday for 1 week (minimum
5 measured days) (nonoverlapping weekly
windows)
ach day (13). Ventricular pacing 90% for 5 of 7 days
(nonoverlapping weekly windows)
atic ICD shock for an
e and inappropriate
1 shocks during the evaluation period
apy; HF  heart failure; HRV  heart rate variability; ICD  implantable cardioverter-defibrillator;
Start* 906030
* Start =  later of consent date or 
60 days post-implant
Evaluation 1
Diagnostic Risk
Assessment 1
HF Event
Assessment 1
Evaluation 2
Evaluation 3
...Repeat until
End of Follow-up
Diagnostic Risk
Assessment 2
HF Event
Assessment 2
Diagnostic Risk
Assessment 3
HF Event
Assessment 3
Figure 1 Monthly Review Model
Every 30 days the previous 30 days are evaluated for heart failure (HF) device
diagnostic risk and then the subsequent 30 days are evaluated for HF event
risk.d Alg
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Combined HF Device Diagnostics Predict HF April 27, 2010:1803–10nd the prospective risk prediction periods were equal to the
valuation interval.
Continuous variables were presented as means and SDs,
nd categorical variables were presented as frequencies and
ercentages. We used Student t tests to compare continuous
ariables and chi-square tests for categorical variables.
Cox proportional hazards models (15) were used to
etermine the association between patients satisfying the
F device diagnostic criteria during the evaluation period
nd experiencing an HF event during the prospective
valuation period and to estimate the hazard ratios (HRs)
nd the 95% confidence intervals (CIs) of an HF event in a
ubsequent prediction period. For the monthly retrospective
valuation, each patient could have as many as 9 evaluation
eriods. To account for the correlation among evaluation
eriods within a patient, the robust sandwich variance
stimate (16) for the HR was applied. Cox regression
odels were used for adjusting several clinical variables,
ncluding age, sex, ischemic cardiomyopathy, diabetes,
YHA functional class, and use of beta-blockers, diuretics,
r angiotensin-converting enzyme inhibitors/angiotensin
eceptor blockers.
We also conducted a subgroup analysis to establish the
redictive power of the HF device diagnostics within the 2
ollowing subgroups: 1) patients without a previous HF
vent; and 2) patients with a previous HF event. We
erformed the subgroup analysis by dividing patients’ eval-
ations into 2 groups: those with and without HF events in
he previous evaluation periods. In patients with an HF
vent, all evaluation periods for that patient were considered
o be in the HF group after the initial event.
All statistical tests were conducted at a significance level
f 0.05, and all statistical analyses were performed using
AS software (version 9.1, SAS Institute Inc., Cary, North
arolina).
esults
atient demographics and events. A total of 1,024 pa-
ients were enrolled at 100 centers in the United States. The
resent analysis included all 694 patients who had
edtronic CRT-D with a fluid index-monitoring capabil-
ty. All patients were followed for at least 5 months, with an
verage follow-up of 11.7  2.0 months. Patient demo-
raphic and medication information is shown in Table 2.
atients in this study were typical of a CRT-D patient
opulation: the majority had an ischemic cardiomyopathy,
5% had an NYHA functional class III HF status at the
eginning of the study, and one-fourth of the patients had
history of AF. Most patients were receiving angiotensin-
onverting enzyme inhibitors or angiotensin receptor block-
rs (81%) as well as beta-blockers (89%) and diuretics (83%).
Ninety (13%) patients had 141 adjudicated HF hospital-
zations with pulmonary congestion. The overall event rate
or the individual evaluation periods was very low due to the tigh number of evaluations, especially for semimonthly and
onthly periods. The percentages of evaluations with a
ulmonary HF hospitalization were as follows: monthly,
.4% (78 events/5,693 evaluations); quarterly, 3.2% (60 HF
vents/1,854 evaluations); and semimonthly, 0.76% (87
vents/11,452 evaluations). In the 120 (17.3%) patients who
ad at least 1 HCU, the total number of HCUs with
ulmonary congestion was 213. These 213 HCUs included
he 141 HF hospitalizations as well as 51 unscheduled office
isits, 5 urgent care visits, and 100 emergency department
isits. Of 694 patients, 15 (2.2%) died.
ombined algorithm performance. The combined algo-
ithm triggered criteria in 23% (1,324 of 5,693) of the
valuations and in 43% (298 of 694) of the patients. Figure 2
hows a breakdown of which individual parameters were
aseline Patient Characteristics (n  694)Table 2 Baseline Patient Characteristics (n  694)
Age (yrs) 68.4 (10.7)
Males 67.3
Ethnic origin
African American 10.7
Caucasian 85.3
Hispanic 0.7
Native American 0.6
Other or no information 2.9
% patients with LVEF 35% 99.1
% patients with QRS duration 130 min 99.3
Heart failure etiology
Ischemic 62.2
Nonischemic 37.8
Diabetes (type 1 or 2) 42.4
Respiratory 57.5
COPD 19.2
Atrial fibrillation 25.8
Chronic/permanent 1.2
Persistent 3.2
Paroxysmal 22.0
New York Heart Association functional class
III 94.8
IV 5.2
ACC/AHA heart failure stage
C 98.3
D 1.7
Cardiovascular medications
Anticoagulants/antiplatelets 84.1
ACE inhibitors or ARBs 82.6
Beta-blockers 90.6
Antiarrhythmics (class I/III) 16.9
Cardiac glycosides 34.7
Diuretics 83.6
Vasodilators/nitrates 29.8
Lipid-lowering medications 69.2
alues are mean (SD) or %.
ACC/AHA  American College of Cardiology/American Heart Association; ACE  angiotensin-
onverting enzyme; ARB  angiotensin receptor blocker; COPD  chronic obstructive pulmonary
isease; LVEF  left ventricular ejection fraction.riggered. Two or more of the 8 criteria were triggered in
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April 27, 2010:1803–10 Combined HF Device Diagnostics Predict HF2% of the algorithm triggers, whereas a fluid index of
100 alone was triggered in an additional 28%. In the 954
valuations with 2 criteria triggered, a high fluid index,
ow activity, and low heart rate variability were the most
ommon criteria met, followed by long AF duration, low
RT pacing, high night heart rate, rapid ventricular rate
uring AF, and ICD shocks. Three criteria were triggered
n 20% of the evaluations and 4 or 5 in the remaining 8%.
Figure 3 shows the Kaplan-Meier survival curve for
onthly evaluations. Compared with patients with a nega-
21%
7%
67%
14%
43%
18%
5%
62%
0%
20%
40%
60%
80%
% Triggered Evaluations        43%        29%        28%
(N = 1324)
≥ 2 Diagnostic Criteria Met
OptiVol ≥100 Met
AF    AF+RVR   OptiVol Low     High night    Low        Low ICD
≥60      activity   heart rate    HRV     Pacing%  Shock(s)
AF           Fluid   Activity  Autonomics  Device Therapy
% of Evaluations
when ≥2 
Diagnostic 
Criteria Met
(N = 960)
N = 960 Evaluations
Figure 2 Combined HF Device Diagnostics Triggered
The Venn diagram shows that 72% of evaluations had 2 HF device diagnos-
tics triggered with the remaining 28% triggered by OptiVol Fluid Index 100.
OptiVol Fluid Index, low activity, and low heart rate variability (HRV) were the
most common reasons for triggers. AF  atrial fibrillation; ICD  implantable
cardioverter-defibrillator; RVR  rapid ventricular response; other abbreviation
as in Figure 1.
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Figure 3
Kaplan-Meier Estimates of the Percentage of Monthly
Evaluations With a Subsequent HF Hospitalization
Due to Sign/Symptoms of Pulmonary Congestion
Patients with a positive combined HF device diagnostic algorithm had a 5.5-
fold increased risk of a subsequent HF event within 30 days. CI  confidence
interval; other abbreviation as in Figure 1.wive combined HF device diagnostic, patients with a positive
ombined HF device diagnostic had a significantly increased
isk of an HF hospitalization with pulmonary congestion
ithin the next month (HR: 5.5, 95% CI: 3.4 to 8.8), p 
.0001). The combined algorithm was also good at identi-
ying which patients were at low risk of subsequent HF
vents as only 0.7% of patients with a negative HF device
iagnostic had an HF hospitalization during the subsequent
0 days. After adjusting for clinical variables known to affect
he occurrence of HF events (Fig. 4), patients with a
ositive combined HF device diagnostic had a 4.8-fold
ncreased risk (HR: 4.8, 95% CI: 2.9 to 8.1, p  0.0001) of
subsequent HF hospitalization with pulmonary conges-
ion independent of the other clinical variables. None of the
ther predefined clinical variables significantly identified
atients at a higher risk of an HF event.
ther analyses. In addition to the combined algorithm
erformance, we analyzed the performance of various com-
onents of the combined algorithm (Fig. 5A). Increasing
he fluid index thresholds resulted in higher HRs. A low
60) fluid index threshold identified patients at a 2.7-fold
isk of HF hospitalization with pulmonary congestion;
owever, a high (100) fluid index increased the HR to 3.9
p  0.0001 for both). The HR (3.2) for 1 of the 7 HF
evice diagnostic criteria met (excluding fluid index) was
imilar to the HR (3.3) for a fluid index80. Requiring any
of the 7 HF device diagnostic criteria (excluding fluid
ndex) increased the HR dramatically but resulted in a
maller subset of patients meeting that condition.
A subanalysis to determine the algorithm performance in
atients with as opposed to without a previous HF event
uring the simulated evaluations revealed 63 evaluations
P-Value
0.90
0.15
0.91
0.18
0.06
0.35 
0.70
0.90
<0.0001
0.25 0.50 1.00 2.00 4.00 8.000.25         0.5        1.0          2.0          4.0         8.0     
Hazard Ratio
* Before evaluation date
Age
Gender
Heart Failure Etiology
NYHA Class*
Diabetes (@baseline)
Diuretics*
ACEI/ARB*
Beta-Blockers*
+ Combined Diagnostic
1
0.7
1
1.4
1.6
1.6
0.7
0.9
4.8
Figure 4 Multivariable Analysis
Patients with a positive combined HF device diagnostic had a 4.8-fold
increased risk of an HF event within 30 days after adjusting for clinical vari-
ables. ACEI/ARB  angiotensin-converting enzyme inhibitor/angiotensin receptor
blocker; NYHA  New York Heart Association; other abbreviation as in Figure 1.ith HF hospitalizations in which the patient did not have
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Combined HF Device Diagnostics Predict HF April 27, 2010:1803–10previous HF hospitalization during the study. For these
atients, the combined algorithm identified patients who
ad a 5.4-fold increased risk (HR: 5.4, 95% CI: 3.2 to 9.0,
 0.0001) of HF hospitalization within the following
onth, as shown in Figure 5. The HR remained high after
djusting for the clinical variables (HR: 4.7, 95% CI: 2.8 to
.0, p  0.0001). There were 15 evaluations with an HF
ospitalization in patients who already had an event earlier
n the study. The combined HF device diagnostic algorithm
id not provide risk stratification in those patients with a
revious event (HR: 0.9, 95% CI: 0.3 to 2.4, p  0.8).
We further sought to understand the effect of less
requent evaluations (quarterly: every 90 days) and more
requent evaluations (semimonthly: every 15 days). The
isk-stratification capability of the combined HF device
Figure 5 Risk Stratification for Different Algorithms,
HF Event History, and Evaluation Frequencies
(A) Various algorithms. An increasingly higher fluid index threshold identifies
patients at higher risk as does combined HF device diagnostic algorithms.
(B) History of HF event. In patients without a previous HF event, the combined
HF device diagnostic did not identify patients at high risk of a subsequent
event; however, in patients without a previous event, the combined HF device
diagnostic algorithm identified patients at a 5.4-fold increased risk of a subse-
quent HF event within 30 days. (C) Evaluation frequency. Increasing the fre-
quency of reviewing the HF device diagnostics from quarterly to monthly will
substantially increase the ability to identify patients at higher risk, whereas
changing from monthly to semimonthly provides a less notable increase. Abbre-
viation as in Figure 1.iagnostic algorithm dropped when we moved from semi- vonthly evaluation to monthly evaluation, and there was a
urther drop when done at quarterly evaluations (semi-
onthly HR of 6.9 vs. monthly HR of 5.5 vs. quarterly HR
f 3.1), as shown in Figure 5C.
iscussion
he PARTNERS HF study is the largest prospective
ohort study evaluating the ability of combined HF device
iagnostics to dynamically risk-stratify patients for HF
vents over set time intervals. Device diagnostic data were
ndependent predictors of HF hospitalizations with pulmo-
ary symptoms. More frequent evaluation of HF device
iagnostics improved the ability to risk-stratify patients for
ubsequent HF events.
In the current study, the use of multiple parameters
ignificantly improved the ability to identify patients at risk
f HF events in the subsequent 30 days beyond the use of
ntrathoracic impedance alone (combined HF device diag-
ostic HR of 5.5 vs. fluid index 60 HR of 2.7). Previous
tudies focused on intrathoracic impedance monitoring to
redict future events without looking at other diagnostic
arameters or they have looked at single HF device diag-
ostic parameters without combining them into an algo-
ithm. The relationship between intrathoracic impedance
nd changes in fluid status has been proven by some studies
hat showed a significant correlation between impedance
easurements and N-terminal pro–B-type natriuretic pep-
ide concentration and pulmonary capillary wedge pressure
17). Relating changes in impedance to HF symptoms and
linical events has been more difficult. Ypenburg et al. (9)
ound that only 33% of the patients (n  15) in their study
ith an OptiVol alert set at 60  had HF symptoms.
ikewise, other studies have looked at other HF device
iagnostics such as night heart rate, heart rate variability,
nd activity but have not coupled them with intrathoracic
mpedance monitoring (7).
Another important finding of our study is that increasing
he frequency of evaluation from quarterly evaluations im-
roves the ability of the combined HF device diagnostic
ata to predict subsequent HF events in the near term. It is
nclear whether this improved ability to risk-stratify pa-
ients will translate into improved outcomes. In past studies
f HF disease management evaluating interventions that
ncluded daily measurement of physiologic parameters
weight, blood pressure, or heart rate) and/or responses to
uestions, these parameters taken together have shown a
ixed impact on hospital admission rates. Investigators in
he SPAN CHF II (Specialized Primary and Networked
are in Heart Failure) study evaluated a home monitoring
ystem providing daily measurements of blood pressure and
eight with patient survey results. These measurements
mproved the 90-day outcomes for HF hospitalization (0.51
s. 1.82 per patient-year, p  0.03) (18). In the Trans-
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April 27, 2010:1803–10 Combined HF Device Diagnostics Predict HFuropean Network Homecare Monitoring Study, the num-
er of all-cause and HF admissions was higher in the daily
elemonitoring cohort compared with usual care (155 vs. 69
or all-cause; 67 vs. 33 for HF hospitalization; no p values
rovided). In the Weight Monitoring in Heart Failure
tudy, twice-daily monitoring had no impact on cardiovas-
ular rehospitalizations (0.11  0.26 vs. 0.08  0.24, p 
.28) (19). These patients were enrolled at the time of
ischarge from the hospital. In the current study, once
atients experienced an HF hospitalization, the ability of
F device diagnostic data to stratify them by risk was
bsent, but no definite conclusions could be drawn regard-
ng this observation due to the small number of events. In
he patients without a previous HF event, the patients with
positive combined HF device diagnostic were 5.4 times
ore likely to have a subsequent event, which suggests the
F device diagnostics can help stratify patients at higher
isk in this important set of patients.
Physicians can now receive reimbursement for remote
onitoring if the HF device diagnostic data are reviewed
very 30 days or less often. The PARTNERS HF investi-
ators identified a large improvement in risk stratification
hen they reduced the duration between evaluations from
0 days to 30 days, but they observed a smaller improvement
n risk stratification when the duration decreased from 30
ays to 15 days. These results suggest that 30 days may be
he optimal time frame for review of HF device diagnostics.
tudy limitations. The present results may be specific to
he device models studied and may not necessarily be
xtrapolated to other devices with different combinations
f parameters because the specific combinations of
evice-derived patient HF device diagnostics can vary
etween models and between manufacturers. Because the
ARTNERS HF study was based on an unblinded pro-
pective registry of HF patients with reduced left ventricular
unction who had received appropriate implantable devices,
he ability of HF device diagnostics to risk-stratify a broader
F population can only be inferred from our results. In
ddition, because clinicians were not blinded to HF device
iagnostic trends, they may have acted on these trends and
hanged the natural course of the disease to avoid a clinical
vent. This type of action would lead to underestimation of
he HF device diagnostic data’s predictive performance.
ikewise, a patient being seen for abnormal HF device
iagnostics for which an HF event was then reported would
esult in an overestimation of the algorithm performance.
owever, this scenario was unlikely to occur because the
dverse Event Advisory Committee adjudicated reported
vents as “no HF event” if the HF device diagnostics were
ndicated as the cause of the event when no other signs or
ymptoms of HF were present. The limited number of
vents warrants replication in a follow-up analysis to verify
ur results.
1onclusions
hanges in HF device diagnostic parameters based on a
ombined algorithm can stratify HF patients for subsequent
F events into high and low risk. The lack of positive HF
evice diagnostic criteria during a 30-day evaluation period
dentified a cohort of patients who were at very low risk of
ubsequent HF clinical events. In contrast, a positive HF
evice diagnostic criterion identified patients who were 4.8
imes more likely to experience an HF hospitalization with
ulmonary congestion in the next 30 days. Although not all
atients subsequently experienced an HF hospitalization
ith pulmonary congestion, the finding that these patients
re at an increased risk of HF events suggests that these
atients have become unstable and should be viewed as high
isk. This study was not a randomized trial to determine
hether clinical interventions based on the HF device
iagnostics will improve outcomes. Future studies are
eeded to test that hypothesis.
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